Sun Pharma and Moebius Medical have received fast track designation from the USFDA for their non-opioid therapy MM-II, aimed at treating osteoarthritis knee pain. This designation allows for expedited review and potentially accelerated approval. The companies plan to initiate Phase 3 clinical trials and seek a CE Mark in the European Union.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.